October is
Liver Cancer
Awareness Month
Every year, about 90.000 people are diagnosed with liver cancer, while approximately 80.000 people sadly pass away from this disease, putting liver cancer in the seventh position as the most frequent cancer-related cause of death in Europe.
It is never too early to act
We encourage you to get involved with our Liver Cancer Awareness campaign!
DiCE has partnered with the European Association for Study of the Liver (EASL), The European Liver Patient Association (ELPA), The International Liver Cancer Association (ILCA) and the International Liver Cancer Movement (ILCM).
Together, we have produced a campaign that encompasses social media interactions, webinars, podcasts, patient stories, and other activities.
United Against Liver Cancer, we aim to raise awareness about liver cancer and the importance of prevention, early diagnosis and best practice care.
There will be two webinars bookending the month.
You can look forward to hearing from expert speakers and patient advocates from all fields of liver cancer.
United
Against Liver Cancer
This webinar is organized jointly by DiCE and several liver organisations with whom we partner. Speakers will discuss policy, prevention, early diagnosis, liver cancer research projects, and advocacy, and there will be a Q&A session.
Liver Cancer:
It is never too early to act
DiCE will host this webinar. Dr Maria Reig, Barcelona Liver Cancer Clinic, Spain and Dr Jeroen Dekervel, Leuven Hospital, Belgium, will speak alongside representatives from liver cancer organisations. There will also be a Q&A session.
Liver Cancer Awareness Month
in 3 main actions
1. Equity
in treatment
DiCE is committed to working towards a future where everyone has access to best practice care, and no patient is left behind. We aim to work together with all stakeholders in the field to ensure that best practices are implemented at every stage of the patient pathway in each country, giving every patient the best possible opportunity of a positive outcome.
2. Screening
for high-risk patient population
DiCE recommends improving the implementation of screening programmes to identify at-risk populations, following the EASL guidelines and/or ESMO guidelines. Patients at high risk of developing liver cancer should be entered into surveillance/screening programmes.
All individuals at high risk should be screened by use of abdominal ultrasound examinations every 6 months.
3. Research
Our research efforts are targeted at understanding the status quo of prevention, diagnosis, treatment, and care of liver cancer across Europe, in order to identify the gaps, inequities in these fields, as well as opportunities to advance access to best practice care for all patients.
This year, we have conducted an extensive research project to map the liver cancer treatment landscape across the EU. The Liver Cancer Index showcases our findings, and we have produced a report summarising the most important points where improvements could be made across the EU to ensure that all patients receive the care they deserve.
1. Equity
in treatment
DiCE is committed to working towards a future where everyone has access to best practice care, and no patient is left behind. We aim to work together with all stakeholders in the field to ensure that best practices are implemented at every stage of the patient pathway in each country, giving every patient the best possible opportunity of a positive outcome.
2. Screening
for high-risk patient population
DiCE recommends improving the implementation of screening programmes to identify at-risk populations. DiCE recommends improving the implementation of screening programmes to identify at-risk populations, following the EASL guidelines and/or ESMO guidelines. Patients at high risk of developing liver cancer should be entered into surveillance/screening programmes. All individuals at high risk should be screened by use of abdominal ultrasound examinations every 6 months.
3. Research
Our research efforts are targeted at understanding the status quo of prevention, diagnosis, treatment, and care of liver cancer across Europe. Our research efforts are targeted at understanding the status quo of prevention, diagnosis, treatment, and care of liver cancer across Europe, in order to identify the gaps, inequities in these fields, as well as opportunities to advance access to best practice care for all patients. This year, we have conducted an extensive research project to map the liver cancer treatment landscape across the EU. The Liver Cancer Index showcases our findings, and we have produced a report summarising the most important points where improvements could be made across the EU to ensure that all patients receive the care they deserve.
VIDEO
Download campaign materials
Social Media Calendar
Social Media Templates
White Paper
White Paper Summary
LCI Executive Summary
Key Facts
Cost of Liver Cancer
Prevention
Taking action against liver cancer starts with prevention. Prevention is more effective than any cure. Many liver cancers could be prevented by tackling known risk factors for this disease, which include viral hepatitis, excessive alcohol consumption, smoking and obesity. You can lower your risk by minimising your alcohol consumption, quitting smoking (or not starting at all) and taking care of your health through exercise, for example making sure you take regular walks.
DiCE has developed StepApp®, a free step counter app that raises awareness for digestive cancers across Europe. It empowers you to stay motivated and fit while helping positively impact society.
Through StepApp®, Digestive Cancers Europe (DiCE) and our Member Organisations are raising awareness of digestive cancers and the importance of prevention, screening, and early diagnosis.
StepApp® is available on Google Play and App Store.
